Organization | Azienda Ospedaliera Universitaria Senese

Azienda Ospedaliera Universitaria Senese Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Siena Italy (1975)

Organization Overview

First Clinical Trial

2007

NCT00466726

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Azienda Ospedaliera Universitaria Senese | Nouvo Policlinico LE SCOTTE'

Active Ingredients

Drugs in Phase 4 Trials (1)

inactivated influenza vaccine (1 trial)

Drugs in Phase 3 Trials (6)

abacavir (ziagen) (1 trial)

bictegravir (Biktarvy) (1 trial)

dolutegravir (tivicay) (2 trials)

emtricitabine (emtriva) (1 trial)

lamivudine (epivir) (2 trials)

tenofovir alafenamide (genvoya) (1 trial)

Drugs in Phase 2 Trials (4)

bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine (1 trial)

daratumumab (darzalex) (1 trial)

sargramostim (leukine) (1 trial)

tremelimumab (Imjudo) (2 trials)

Drugs in Other Trials (5)

alpha-lactalbumin (1 trial)

fructo-oligosaccharide (1 trial)

inulin (1 trial)

sodium butyrate (1 trial)

zinc oxide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Influenza, Human (Phase 4)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 16